Journal
BLOOD
Volume 112, Issue 5, Pages 2017-2019Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-01-135186
Keywords
-
Categories
Funding
- Intramural Research Program of the NIH and NCI
- NATIONAL CANCER INSTITUTE [ZIABC010982, Z01BC010982] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The NUP98-HOXD13(NHD13) fusion gene occurs in patients with myelodysplastic syndrome (MDS) and acute nonlymphocytic leukemia (ANLL). We reported that transgenic mice expressing NHD13 develop MDS, and that more than half of these mice eventually progress to acute leukemia. The latency period suggests a requirement for at least I complementary event before leukemic transformation. We conducted a candidate gene search for complementary events focused on genes that are frequently mutated in human myeloid leukemia. We investigated 22 ANLL samples and found a high frequency of Nras and Kras mutations, an absence of Npm1, p53, Runx1, Kit and Flt3 mutations, and a single Cbl mutation. Our findings support a working hypothesis that predicts that ANLL cases have one mutation which inhibits differentiation, and a complementary mutation which enhances proliferation or inhibit apoptosis. In addition, we provide the first evidence for spontaneous collaborating mutations in a genetically engineered mouse model of ANLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available